BMY 20844

BMY 20844 is an orally active platelet cAMP phosphodiesterase inhibitor with anti-thrombosis activity. BMY 20844 can elevate cAMP levels and activate protein kinase in platelets. BMY 20844 can be used for the research of cardiovascular disease[1][2].

Product Specifications

CAS Number

[124886-01-7]

UNSPSC

12352005

Target

Phosphodiesterase (PDE)

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Smiles

O=C1N=C2NC3=CC=C(C)C(C)=C3C=C2N1

Molecular Formula

C12H11N3O

Molecular Weight

213.24

References & Citations

[1]Seiler S, et al. Imidazoquinoline derivatives: potent inhibitors of platelet cAMP phosphodiesterase which elevate cAMP levels and activate protein kinase in platelets. Thromb Res. 1991 Apr;62 (1-2) :31-42.|[2]Buchanan JO, et al. Pharmacology of a potent, new antithrombotic agent, 1,3-dihydro-7,8-dimethyl-2H-imidazo[4,5-b]quinolin-2-one (BMY-20844) . Thromb Res. 1989 Nov 1;56 (3) :333-46.